Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / LZTS1

LZTS1

Basics

Aliases:
This biomarker is also known as:
  • FEZ1,
  • leucine zipper, putative tumor suppressor 1,
  • leucine zipper putative tumor suppressor 1,
  • Q9Y250,
  • F37,
  • F37/esophageal cancer-related gene-coding leucine-zipper motif,
  • Fez1,
  • F37/Esophageal cancer-related gene-coding leucine-zipper motif,

View in BioMuta

Description…

LZTS1 is a tumor suppressor protein that is widely expressed in normal tissues. It is involved in regulating cell growth and is also thought to interact with the active CDC2-cyclin B1 complex and contribute to the regulation of the cell cycle and the prevention of uncontrolled cell proliferation. Loss of heterozygosity (LOH) in the 8p arm is a common characteristic of many types of cancer, and this gene is located on 8p22.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: One
QA State: Under Review

Overview

LZTS1 may be considered for further preclinical testing as a tumor biomarker.

Performance Comment

LZTS1 was overexpressed in ovarian cancer relative to normal ovary and relative to a panel of normal organs. LZTS1 was found in small and larger blood vessels. FZD10 showed limited or no expression by qRT-PCR in normal tissues.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html